These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 31852408)

  • 21. Inhaled treatment of COPD: a Delphi consensus statement.
    Ninane V; Corhay JL; Germonpré P; Janssens W; Joos GF; Liistro G; Vincken W; Gurdain S; Vanvlasselaer E; Lehouck A
    Int J Chron Obstruct Pulmon Dis; 2017; 12():793-801. PubMed ID: 28293106
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Current position of new fixed-dose combination of tiotropium and olodaterol - its role in the treatment of chronic obstructive pulmonary disease in the Czech Republic].
    Koblížek V; Svoboda M
    Vnitr Lek; 2016; 62(12):1011-1020. PubMed ID: 28139131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine.
    Contoli M; Corsico AG; Santus P; Di Marco F; Braido F; Rogliani P; Calzetta L; Scichilone N
    COPD; 2017 Dec; 14(6):641-647. PubMed ID: 29116901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-acting beta-agonists and their association with inhaled corticosteroids in COPD.
    Fuso L; Mores N; Valente S; Malerba M; Montuschi P
    Curr Med Chem; 2013; 20(12):1477-95. PubMed ID: 23409722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bronchodilator combination therapy for the treatment of chronic obstructive pulmonary disease.
    Sethi S; Cote C
    Curr Clin Pharmacol; 2011 Feb; 6(1):48-61. PubMed ID: 21235463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Asthma and COPD: guidance in the jungle of inhalative drugs].
    Hering T
    MMW Fortschr Med; 2015 May; 157(10):59, 61-2. PubMed ID: 26019099
    [No Abstract]   [Full Text] [Related]  

  • 27. Perplexing mortality data from triple therapy trials in COPD.
    Suissa S
    Lancet Respir Med; 2021 Jul; 9(7):684-685. PubMed ID: 34126054
    [No Abstract]   [Full Text] [Related]  

  • 28. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
    Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What is the role of triple inhaled therapy in COPD?
    Petite SE
    JAAPA; 2019 Oct; 32(10):44-45. PubMed ID: 31567741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis.
    Price D; Miravitlles M; Pavord I; Thomas M; Wedzicha J; Haughney J; Bichel K; West D
    NPJ Prim Care Respir Med; 2016 Nov; 26():16061. PubMed ID: 27808096
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD.
    Cazzola M; Molimard M
    Pulm Pharmacol Ther; 2010 Aug; 23(4):257-67. PubMed ID: 20381630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium.
    Ficker JH; Rabe KF; Welte T
    Pulm Pharmacol Ther; 2017 Aug; 45():19-33. PubMed ID: 28389258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-acting muscarinic antagonist + long-acting beta agonist versus long-acting beta agonist + inhaled corticosteroid for COPD: A systematic review and meta-analysis.
    Horita N; Miyazawa N; Tomaru K; Inoue M; Kaneko T
    Respirology; 2015 Nov; 20(8):1153-9. PubMed ID: 26235837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Inhaled corticosteroid/beta-2 agonist therapy in moderate COPD].
    Yıldırım N
    Tuberk Toraks; 2010; 58(2):192-201. PubMed ID: 20865575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacological basis and scientific rationale underlying the targeted use of inhaled corticosteroid/long-acting β2-adrenergic agonist combinations in chronic obstructive pulmonary disease treatment.
    Pelaia G; Muzzio CC; Vatrella A; Maselli R; Magnoni MS; Rizzi A
    Expert Opin Pharmacother; 2015; 16(13):2009-21. PubMed ID: 26194120
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What is in the guidelines about the pharmacological treatment of chronic obstructive pulmonary disease?
    López-Campos JL; Calero Acuña C
    Expert Rev Respir Med; 2013 Apr; 7(2 Suppl):43-51. PubMed ID: 23551023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An evaluation of early medication use for COPD: a population-based cohort study.
    Falk J; Dik N; Bugden S
    Int J Chron Obstruct Pulmon Dis; 2016; 11():3101-3108. PubMed ID: 27994449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological approach and adherence to treatment recommendations in frequently and non-frequently exacerbating COPD patients from Italy: MISTRAL - The prospective cohort, observational study.
    Scalone G; Nava S; Ventrella F; Bussoli G; Catapano GA; Pennisi A; Dadduzio F; Schino P; Pela R; Bartezaghi M; Morini P; Porpiglia PA; Muscianisi E;
    Pulm Pharmacol Ther; 2018 Dec; 53():68-77. PubMed ID: 30193866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review.
    Miravitlles M; D'Urzo A; Singh D; Koblizek V
    Respir Res; 2016 Sep; 17(1):112. PubMed ID: 27613392
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [New bronchodilators and combinations in COPD treatment].
    Günay S; Sarıaydın M; Yılmaz Demirci N
    Tuberk Toraks; 2016 Sep; 64(3):240-245. PubMed ID: 28366158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.